Verona Pharma plc
VRNA
Κατάταξη σε μετοχές
#2233
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Τιμή μετοχής
$106.91
Τελευταίος συγχρονισμός: 2025-10-07
Κεφαλαιοποίηση
$9.09B
Αλλαγή (1 ημέρα)
0.00%
Αλλαγή (1 έτος)
0.00%
Χώρα
GB
Εμπόριο Verona Pharma plc (VRNA)
Κατηγορία
Healthcare
Δείκτης P/S για Verona Pharma plc (VRNA)
Δείκτης P/S στις October 2026 TTM: 2.15K
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή μετοχής της Verona Pharma plc, ο τρέχων δείκτης P/S (TTM) είναι 2.15K. Στο τέλος του 2023, ο δείκτης ήταν 0.00.
Ιστορικό P/S για την Verona Pharma plc από 2005 έως 2026
Δείκτης P/S στο τέλος κάθε έτους
| Έτος | P/S Ratio | Αλλαγή |
|---|---|---|
| 2026 (TTM) | 2.15K | 1,849.31% |
| 2024 | 110.41 | 0.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | 3.77K | 37,827.00% |
| 2021 | 9.94 | 0.00% |
| 2020 | 0.00 | -100.00% |
| 2019 | 24.28K | -32.01% |
| 2018 | 35.71K | 65,523.71% |
| 2017 | 54.42 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
Δείκτης P/S για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | P/S Ratio | Διαφορά P/S Ratio | Χώρα |
|---|---|---|---|
| 10.02 | -99.53% |
US
|
|
| 40.55 | -98.12% |
US
|
|
| 3.96 | -99.82% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -99.53% |
NL
|
